logo
  Join        Login             Stock Quote

Eli Lilly (LLY) 1Q Earnings Drop As Zyprexa Weighs, Raises Forecast As EPS Tops Consensus

 April 25, 2012 06:55 AM
 


(By Balachander S) Eli Lilly & Co. (NYSE:LLY) reported a drop in quarterly earnings, as Zyprexa patent expirations drove lower revenue and margins. Yet, the bottom-line topped Wall Street projections and the company raised its full-year forecast.

On a non-GAAP basis, earnings per share (EPS) declined 26 percent to $0.92 from $1.24, but beat market expectations of $0.78 per share.

Net earnings fell 4 percent to $1.01 billion or $0.91 per share for the first quarter from $1.05 billion or $0.95 per share in the year-ago quarter.

Total revenue dropped 4 percent to $5.6 billion, hurt by patent expirations of anti-psychotic drug Zyprexa, yet beat consensus estimate of $5.36 billion.

[Related -Is This The Start Of A Correction?]

Gross margin contracted 1.2 percentage points to 78.6 percent.

Volumes dipped 7 percent due to the loss of patent exclusivity for Zyprexa in most major markets.

Total revenue in the U.S. remained unchanged at $3.085 billion, while falling 9 percent outside the U.S.

Research and development and marketing, selling and administrative increased 2 percent and 3 percent, respectively.

Looking ahead for the full year, the company now expects non-GAAP earnings per share in the range of $3.15 to $3.30 from prior expectations of $3.10 to $3.20. Revenue is still projected to be between $21.8 billion and $22.8 billion. Analysts expect earnings of $3.18 per share on revenue of $22.4 billion.

LLY expects gross margin to be around 77 percent for the year.

The stock, which has been trading between $33.75 and $42.03 over the past year, ended Tuesday's regular trading at $39.96.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChart Says This Retailer's Comeback Isn't Finished

One of the surprises, at least on the surface, of the market's recent swoon was the outperformance of read on...

article imageETF Performance Review: Major Asset Classes | 19 Dec 2014

It’s all about real estate investment trusts (REITs) these days when it comes to bullish performance among read on...

article imageOil and Global Stock Markets Rebounding Sharply

So far so good on our expectation of a 4 to 5% pullback and then a resumption of the bull read on...

article imageGrading the FOMC

Love its members or loathe them, you have to admire the gradual impact the policy-making committee has had read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.